Afatinib is a second-generation, irreversible ErbB-family blocker [10] that is approved in many countries, including Japan [11], for the first-line treatment of patients with EGFR mutation-positive NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.